HealthDay on MSN1d
Baseline Characteristics ID Risk for Recurrent Endoscopic Sinus Surgery
THURSDAY, Feb. 6, 2025 (HealthDay News) -- A few baseline characteristics can predict the need for recurrent endoscopic sinus ...
Hosted on MSN1mon
GSK’s Nucala approved in China as add-on therapy for adults with CRSwNP
CRSwNP, for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. It is estimated that about 107 million people in China suffer from chronic sinusitis ...
Buy11d
GSK applications for sinus disease treatment accepted for review
(Alliance News) - GSK PLC on Tuesday said applications for its treatment for a type of asthma and chronic rhinosinusitis with nasal polyps, or CRSwNP, have been accepted for review in China, Japan and ...
Nasdaq1mon
GSK’s Nucala Gains Approval in China for CRSwNP
Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 million people in the country. This approval ...